Systemic sclerosis & Raynaud's
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)
Authors' conclusion
This study has identified anti-PRMT5 antibodies as a novel biomarker for SSc.
Study context
- Population
- Patients with SSc, healthy donors and patients with other autoimmune conditions (SLE, Sjögren's syndrome); PRMT5-immunised mice
- Comparison
- Anti-PRMT5 antibodies in SSc vs healthy controls and other autoimmune conditions (SLE, Sjögren's syndrome)
- Outcome
- Anti-PRMT5 antibodies in SSc
Methodological detailsIP-MS-based quantitative proteomics, orthogonal validation in two independent SSc groups, microarray, mouse immunisation model
- IP-MS-based quantitative proteomics
- Orthogonal validation in two independent SSc groups
- Microarray
- Mouse immunisation model
Performance
As reported in the abstract
AUC distinguishing SSc from healthy controls and other autoimmune conditions (SLE, Sjögren's syndrome)
0.900 to 0.988
Patients with SSc seropositive for anti-PRMT5 antibodies
31.11%
Further findings
Elevation verified in an independent SSc group by microarray
- Elevation of anti-PRMT5 antibodies verified
Anti-PRMT5 titres and disease course
- Titres correlated with progression or regression trajectory in SSc
PRMT5 immunisation in mice
- Significant inflammation and fibrosis in skin and lungs, with upregulation of multiple proinflammatory and profibrotic pathways
Original publication
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc). Ann Rheum Dis. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →